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We appreciate Ruhl and Everhart’s comment [1]
about our study [2]. The authors raise two important
issues. The ﬁrst issue is whether NAFLD is associated
with adverse outcomes. And, second, what statistical
package should be used for the analysis of NHANES-
NDI linked database.
Over the past decade, a number of studies have con-
sistently shown that a subtype of NAFLD has a poten-
tially progressive course. The data supporting this
notion comes from tertiary care medical centers [3–5],
paired liver biopsies [6–8] and a community-based study
[9]. Additionally, NHANES database has been used by
three in dependent groups [2,10]. The ﬁrst and second
studies suggested an increased all cause mortality [2]
and increased all cause mortality only in the 45-54 age
group [10]. The third study, did not show an increase
in mortality [11]. We suspect that diﬀerences in study de-
sign, selection of NAFLD patients, the control cohort,
disease deﬁnitions as well as strategies for data analysis
may explain these diﬀerences. Despite this diﬀerence, we
believe that most of the available evidence supports the
notion that at least a subgroup of patients with NAFLD
can progress and develop adverse outcomes.
The second issue raised by the authors relates to the
statistical package for analysis of NHANES data used
in diﬀerent studies [2–11]. We do agree with the authors
about the complexity of NHANES data analysis. Never-
theless, SAS survey functions, SUDAAN, and STATA
are all recommended byCDC forNHANESdata analysis
(Dec 2005 updates toAnalyticGuidelines). Currently, the
NHANES tutorial includes instructions for users who
prefer to use any of these three statistical tools. However,
it is important to emphasize that the sampling analysis of
the NHANES requires special attention because of the
weighting procedure that is included in order to keep
the population’s representativeness. While calculations
of means for such designs are typically straightforward,
variance estimation in a stratiﬁed sampling is a tricky pro-
cedure because for complex sample surveys, exact mathe-
matical formulas for variance estimates are usually not
available. Two methods exist for variance estimation
developed for stratiﬁed sampling such as NHANES: the
Taylor linearization and the replication method. The lat-
ter is not implemented in the SAS survey functions. Cur-
rently, however,NCHS recommends the use of theTaylor
Series Linearization methods for variance estimation in
all NHANES surveys. SUDAAN, STATA, and the
SAS Survey procedures can be used to obtain variance
estimated by this method [12].
The diﬀerence between SAS survey function and
SUDAAN occurs when one wants to calculate conﬁ-dence intervals or perform statistical tests. For that pur-
pose, one needs not only estimate for means and
variances, but also the behavior (the degrees of freedom)
for their distributions. Typically, the number of degrees
of freedom for statistical tests is related to the number of
independent objects included in these tests. There is a
known limitation in SAS functions in estimating the de-
grees of freedom for statistical tests when not all the
strata are present in the sub-population of interest (typ-
ically, when the sub-population is small): thus, SAS
overestimates the degrees of freedom and returns
slightly biased conﬁdence intervals. This issue is ad-
dressed in the NHANES guidelines and has been consid-
ered. Another limitation of SAS is that the calculation
of percentiles is not implemented within it; this can be
important for some designs.
In amore complex analysis such as regression analyses,
SAS procedures require additional attention because all
but the very last SAS versions (SAS 9.2) do not have the
necessary options implemented by default. Speciﬁcally,
for correct weighting, the domain option should be used
in a regression procedure, and this option is not included
in the SAS 9.1 and older versions. This can be addressed
by downloading the necessary SAS patch. After that,
however, the SAS regression procedure is as reliable as
SUDAAN’s, and the only diﬀerence occurs when one
wants to calculate conﬁdence intervals – SAS handles
the degrees of freedom in a diﬀerent way and the intervals
(though not the estimates themselves) could be slightly
diﬀerent in certain cases.
In a recent publication, SAS survey function and
SUDAAN were compared [13]. In this study, authors
duplicated previously reported SUDAAN calculations
using SAS procedures [13]. The resulting output was
not signiﬁcantly diﬀerent from that of SUDAAN.
The authors concluded that the survey functions of
SAS could be used for NHANES analysis if a num-
ber of additional previously described steps are taken
[13].
In conclusion, we agree with Ruhl et al. that analysis
of NHANES database requires careful consideration as
well as following the appropriate guidelines recom-
mended by NCHS. Furthermore, we agree that when
in doubt, both SAS and SUDAAN should be used for
the analysis of NHANES data.
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To the Editor:
In the Journal Club section of the Journal, Wang and
Thorgeirsson [1] discussed our recent manuscript [2],
and provided a comprehensive overview and thoughtful
comments on the topic. However, their comment, ‘‘the
proﬁling of 6000 transcriptionally informative genes
could be the explanation why this report fails to identify
tumor-associated survival genes”, is misleading.
The informative gene panel was not deﬁned based on
abundance of transcripts, but on variation across sam-
ples, i.e., genes highly expressed in a subset of samples
but silenced in the rest were more likely to be chosen
as informative genes. In fact, most of the genes known
to be silenced due to epigenetic modiﬁcation in human
cancers, e.g., IGF2, CDKN2A (p16), CDH1 (E-cad-
herin), CDH13, APC, SOCS1, MGMT, and DAPK1,
are included in the panel (NCBI Gene Expression Omni-
bus platform Accession ID: GPL5474).
It is true that dysregulation of key molecular regula-
tors like p53 and MYC often cannot be captured by
transcripts of themselves. However, downstream eﬀect
of the dysregulation can be reproducibly captured in[11] Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase
and gammaglutamyltransferase and mortality in the United States
population. Gastroenterology 2009;136:477–485.
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lar carcinoma
transcriptome space as a ‘‘signature” [3,4]. As we
showed in the manuscript, the informative gene panel
was tailored for such ‘‘signature”-based transcriptome
analysis, and the majority of various published tumor-
derived signature genes are covered by the panel [2]. In
fact, the hepatocellular carcinoma (HCC) tumor-derived
survival predictive gene signature reported by Lee et al.
[5] was perfectly recapitulated using the panel [2]. These
clearly indicate that coverage in the panel is suﬃcient to
analyze tumor-derived molecular information. Further-
more, we could not ﬁnd any survival-correlated genes
in standard whole-genome gene-expression data gener-
ated on frozen HCC specimens (unpublished data).
Thus, we concluded that the lack of tumor-derived
survival-correlated gene is not due to the ‘‘informative
gene” proﬁling approach, but rather due to spectrum
of the type of recurrence in analyzed patient series.
The extent of association between tumor-derived infor-
mation and patient survival is unstable depending on
which of ‘‘early” or ‘‘late” recurrence is the major driver
of survival in each particular patient series analyzed in
each study (in other words, how eﬃciently tumor sur-
